Summary
Eli Lilly and Company's (LLY) Q3 2015 report shows a modest revenue increase year-over-year, driven by growth in the U.S. market, partially offset by unfavorable foreign exchange rates impacting international sales. The company saw a significant increase in net income and diluted EPS for the quarter, primarily due to a higher gross margin, decreased operating expenses, and a substantial reduction in acquired in-process research and development (IPR&D) charges compared to the prior year. Key strategic developments include the integration of the Novartis Animal Health acquisition, which contributed to revenue growth in the animal health segment, and ongoing pipeline advancements. However, the company faces ongoing challenges related to patent expirations and generic competition for key products like Cymbalta and Alimta, which are expected to materially impact future revenues. Despite these headwinds, Lilly's financial position remains solid, supported by robust cash generation from operations.
Financial Highlights
53 data points| Revenue | $4.96B |
| Cost of Revenue | $1.24B |
| Gross Profit | $3.72B |
| R&D Expenses | $1.14B |
| SG&A Expenses | $1.58B |
| Operating Expenses | $2.72B |
| Interest Expense | $39.30M |
| Net Income | $799.70M |
| EPS (Basic) | $0.75 |
| EPS (Diluted) | $0.75 |
| Shares Outstanding (Basic) | 1.06B |
| Shares Outstanding (Diluted) | 1.07B |
Key Highlights
- 1Revenue increased by 2% to $4.96 billion for the third quarter of 2015, and by 1% to $14.58 billion for the first nine months, primarily driven by U.S. market growth and the inclusion of Novartis Animal Health revenue.
- 2Net income for the third quarter surged by 60% to $799.7 million, with diluted EPS increasing to $0.75, largely due to improved gross margins, reduced operating expenses, and lower IPR&D charges.
- 3The acquisition of Novartis Animal Health was completed on January 1, 2015, for $5.28 billion, significantly bolstering the animal health segment's revenue.
- 4Significant pipeline progress is noted, with several New Molecular Entities (NMEs) in Phase III trials and some submitted for regulatory review, including abemaciclib for breast cancer and ixekizumab for psoriasis.
- 5The company faces material risks from patent expirations and the entry of generic competition, particularly for Cymbalta (Europe), Alimta (global), and Zyprexa (Japan), which are expected to significantly impact future revenues.
- 6Investments in research and development decreased by 8% year-over-year in the third quarter, and marketing, selling, and administrative expenses decreased by 6%, partly due to favorable foreign exchange rates.
- 7Total debt increased slightly to $8.08 billion, while cash and cash equivalents decreased to $3.24 billion, reflecting ongoing debt management, share repurchases, and acquisition-related payments.